My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amrize Ltd Ordinary Shares (NY:AMRZ)

48.20 -0.27 (-0.55%)
Streaming Delayed Price Updated: 12:42 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amrize Ltd Ordinary Shares

Benson Adds $5.2 Million Stake in Amrize After Holcim Spinoff
Via The Motley Fool
Topics Supply Chain
Amrize Announces Date for Third Quarter 2025 Financial Results
From Amrize
Via Business Wire
A Glimpse Into The Expert Outlook On Amrize Through 5 Analysts
 
Via Benzinga
Amrize Partners with Chicago Architecture Biennial to Advance Building
From Amrize
Via Business Wire
10 Analysts Assess Amrize: What You Need To Know
 
Via Benzinga
Darden, Humana, And Rocket Lab Are Among Top 10 Large Cap Losers Last Week (Sep. 15- Sep. 19): Are The Others In Your Portfolio?
Darden, Humana, Rocket Lab, and FactSet led last week's large-cap losers, with declines driven by weak earnings, guidance, and downgrades. 
Via Benzinga
Alpha Buying: Thin Insider Buying Makes These Recent Purchases Significant
 
Via Benzinga
Amrize Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Investment Corporation
From Amrize Ltd
Via Business Wire
Amrize Delivers Solid Second Quarter, Starts Journey in Position of Strength
From Amrize
Via Business Wire
Amrize Announces Date for Second Quarter 2025 Financial Results
From Amrize
Via Business Wire
Amrize and Meta Partner on First-of-its-kind AI-Optimized Advanced Concrete Mix for Data Center in Minnesota
From Amrize
Via Business Wire
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.